Due to the unprecedented demand on our Infoline and Ask The Nurse services, we have added additional staff to support you.
Please continue to contact us and visit our dedicated COVID-19 Information Hub for the latest information on how measures may apply to you.

Myeloma UK Infoday a success in Oxford

The Spring Infodays came to a close last weekend with a successful event held in Oxford.

Myeloma UK news, Past Infoday // 5th July 2018

The Spring 2018 Infodays came to a close on Saturday 30 June with a successful day held at the Belfry hotel in Oxford. Delegates enjoyed a day filled with interesting and informative talks as wells as interactive workshops.

The Myeloma UK Oxford Infoday was chaired by Dr. Karthik Ramasamy, Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust. Over 90 patients and family members were in attendance, learning more about the disease, living with myeloma and some of the latest developments in research.

All of the sessions for the day were delivered by Myeloma UK staff and local healthcare professionals including; Dr Pratap Neelakantan, Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust; Dr Jaimal Kothari, Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust; Dr Mark Offer, Consultant Haematologist, Frimley Health NHS Foundation Trust and Lisa Ferguson, Myeloma Advanced Nurse Practitioner, Oxford University Hospitals NHS Foundation Trust.


“Another excellent Infoday – very informative and informal. It was nice to have the opportunity to speak to professionals and other myeloma patients.”

Infoday attendee

A discussion on the new RUDY Study was also held by Dr Kassim Javaid, giving a brief overview of how myeloma patients can get involved. RUDY, which stands for Rare and Undiagnosed Diseases Study, aims to improve the understanding of myeloma and other rare diseases through patient driven research. The project is currently being run by a research team at University of Oxford and aims to collect information over a five year period.

The study has been co developed with patients and is accessible online and can also be done by post. This means patients don’t have to take extra trips to the hospital. If you would like to find out more or sign up to participate, visit www.rudystudy.org.

Myeloma patient, Ian Blelloch, brought the informative day to a close as he spoke about his experience of living with myeloma.

Copies of the presentations can be found below, as well as a feedback form for attendees who would like to leave feedback: